Results 141 to 150 of about 657,649 (153)

Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance

European Journal of Medicinal Chemistry, 2022
Hongchuang Xu, Wei Huang, Lin-Sheng Zhuo
exaly  

The promise of TRK inhibitors in pediatric cancers with fusions

Cancer Genetics, 2022
Theodore W Laetsch
exaly  

Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update

Expert Opinion on Therapeutic Patents, 2023
Brent Page, Ralf Schirrmacher, Justin J Bailey   +2 more
exaly  

TRK Inhibitors in Non-Small Cell Lung Cancer

Current Treatment Options in Oncology, 2020
Guilherme Harada
exaly  

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults

Cancer Genetics, 2022
Alexander Drilon, Guilherme Harada
exaly  

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold

European Journal of Medicinal Chemistry, 2022
Dongmei Zhao, Ruifeng Wang
exaly  

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of Oncology, 2020
Alexander Drilon, James J Harding, M Offin   +2 more
exaly  

Role of Neurotrophin-Trk Interactions in Oncology: The Anti-tumor Efficacy of Potent and Selective Trk Tyrosine Kinase Inhibitors in Pre-Clinical Tumor Models

Current Medicinal Chemistry, 1999
Robert L Hudkins, Bruce A Ruggeri
exaly  

Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases

Journal of Medicinal Chemistry, 2008
Michelle L Lamb
exaly  

Discovery of novel indazole derivatives as second-generation TRK inhibitors

European Journal of Medicinal Chemistry
Dongmei Zhao, Qiaohua Qin, Tianxiao Wu
exaly